Olaparib: tested with established drugs
48 studies: they are given beside it. Page 1 of 1. Open to participants first (7), then studies with results posted, then the rest; newest registration first within each.
- Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell TumorsNot yet recruitingNCT07850973Phase 1/2Report a problem
- Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast CancerRecruitingNCT07695259Phase 4Report a problem
- Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial)RecruitingNCT06377267Phase 2Report a problem
- Estradiol Plus Olaparib for Breast Cancer (PHOEBE)RecruitingNCT05900895Phase 1Report a problem
- Pembro With Radiation With or Without OlaparibRecruitingNCT05568550Phase 2Report a problem
- Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectivenessRecruitingNCT05078671Phase 4Report a problem
- Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast CancerRecruitingNCT03150576Phase 2/3Report a problem
- Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate CancerTerminatedNCT05501548Phase 2Results postedReport a problem
- Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)Active, not recruitingNCT05171816Phase 3Results postedReport a problem
- Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell CarcinomaActive, not recruitingNCT04643379Phase 2Results postedReport a problem
- Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)TerminatedNCT04191135Phase 2Results postedReport a problem
- A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)CompletedNCT03976362Phase 3Results postedReport a problem
- Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)CompletedNCT03976323Phase 3Results postedReport a problem
- Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)Active, not recruitingNCT03775486Phase 2Results postedReport a problem
- Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate CancerActive, not recruitingNCT03732820Phase 3Results postedReport a problem
- Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate CancerCompletedNCT03516812Phase 2Results postedReport a problem
- A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)Active, not recruitingNCT03459846Phase 2Results postedReport a problem
- The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.CompletedNCT02430311Phase 1Results postedReport a problem
- Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.CompletedNCT01972217Phase 2Results postedReport a problem
- Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.CompletedNCT01924533Phase 3Results postedReport a problem
- Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking HistoryCompletedNCT01758731Phase 1Results postedReport a problem
- Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib AloneCompletedNCT01513174Phase 1/2Results postedReport a problem
- Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic CancerCompletedNCT01296763Phase 1Results postedReport a problem
- Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer PatientsCompletedNCT01063517Phase 2Results postedReport a problem
- Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate CancerWithdrawnNCT07090369Phase 1Report a problem
- Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment TrialActive, not recruitingNCT05554328Phase 2Report a problem
- Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC PatientsStatus unknownNCT05174832Phase 2Report a problem
- Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical CystectomyTerminatedNCT04579133Phase 2Report a problem
- Neoadjuvant Chemotherapy With PISOXO for Locally-invaded-gastric Cancer (LIGC)Status unknownNCT04410887Phase 1/2Report a problem
- Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine CancerActive, not recruitingNCT04394858Phase 2Report a problem
- Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before SurgeryActive, not recruitingNCT03943173Early Phase 1Report a problem
- Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell TransplantCompletedNCT03259503Phase 1Report a problem
- Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination DeficiencyCompletedNCT02789332Phase 2Report a problem
- A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube CancerActive, not recruitingNCT02489006Phase 2Report a problem
- Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS)CompletedNCT02398058Phase 1Report a problem
- Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before ProstatectomyCompletedNCT02324998Phase 1Report a problem
- Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube CancerCompletedNCT02121990Phase 1Report a problem
- Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian CancerStatus unknownNCT01650376Phase 1/2Report a problem
- Olaparib Dose Escalating Trial + Concurrent RT With or Without Cisplatin in Locally Advanced NSCLCCompletedNCT01562210Phase 1Report a problem
- AZD2281 Plus Carboplatin to Treat Breast and Ovarian CancerCompletedNCT01445418Phase 1Report a problem
- Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s CancersCompletedNCT01237067Phase 1Report a problem
- AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid TumoursTerminatedNCT00819221Phase 1Report a problem
- Phase I AZD2281/Cisplatin in Advanced Solid Tumour PatientsCompletedNCT00782574Phase 1Report a problem
- Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid TumoursCompletedNCT00710268Phase 1Report a problem
- Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast CancerCompletedNCT00707707Phase 1Report a problem
- Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or PaclitaxelCompletedNCT00516724Phase 1Report a problem
- Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With TopotecanCompletedNCT00516438Phase 1Report a problem
- Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic CancerCompletedNCT00515866Phase 1Report a problem